REFLUDAN [lepirudin (rDNA) for injection]: the first direct thrombin inhibitor FDA-approved for heparin induced thrombocytopenia (HIT)

Learn more about the benefits of REFLUDAN
This section contains REFLUDAN laboratory and clinical efficacy data
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes the dosage and administration of REFLUDAN in the treatment of heparin induced thrombocytopenia (HIT)
Heparin induced thrombocytopenia
This section describes the clinical use of heparin and its role in the development of heparin induced thrombocytopenia (HIT)
This section describes the clinical consequences of heparin induced thrombocytopenia (HIT)
This section lists the most frequent thromboembolic complications (TECs) that can develop in patients with heparin induced thrombocytopenia (HIT)
This section includes the severe consequences of heparin induced thrombocytopenia (HIT) and underscores the importance of prompt diagnosis and treatment of patients when HIT is suspected
This section lists the average direct medical charges associated with some of the individual thromboembolic complications (TECs) that may occur in patients with heparin induced thrombocytopenia (HIT)
This section describes the signs of heparin induced thrombocytopenia (HIT) and the timeframe in which they generally occur
This section emphasizes the need for platelet count monitoring in all patients receiving heparin to assist in the identification of patients who develop heparin induced thrombocytopenia (HIT)
This section describes the signs, symptoms, and management of heparin induced thrombocytopenia (HIT)
This section describes the laboratory tests that can be used to confirm heparin induced thrombocytopenia (HIT)
A summary of pivotal trial data for REFLUDAN is covered in this section
This section provides access to a variety of resources to obtain in-depth information on heparin induced thrombocytopenia (HIT) and REFLUDAN
Find out what your peers are saying about heparin induced thrombocytopenia (HIT)...

©2007 Bayer Healthcare Pharmaceuticals Inc. All rights reserved.
H.I.T. BACK with REFLUDAN to protect life and limb
When to Suspect HIT Type 2
The hallmark of HIT is a fall in platelet count to <50% of baseline and/or to <150,000/µL, or the occurrence of an unexplained TEC.2, 11 Onset is typically from 4 to 14 days after initiation of heparin therapy, but may occur within 10 hours in patients recently exposed to heparin (within the previous 100 days).2, 3, 8 The platelet count of a patient with HIT may fall more than 50% from the baseline value but fail to decline to 150,000/µL.2 Although other causes of thrombocytopenia (eg, septicemia, disseminated intravascular coagulation, immune disorders) must first be ruled out,12 HIT should routinely be suspected when any unexpected and substantial percentage decline in platelet count occurs during heparin treatment.2



A diagnosis of HIT should be strongly considered when2, 11:

Heparin induced thrombocytopenia (HIT) should be suspected when any substantial percentage decline in platelet count occurs at any point during heparin therapy



In addition to platelet counts, the occurrence of thromboembolic events, which can occur at any stage in the decline in platelet count, often points to a diagnosis of HIT. In one 14-year study, 51% of patients with serologically confirmed HIT presented with a TEC.11 In addition, the presence of unusual events such as skin lesions at the site of heparin injection, although rare, is usually a sign of HIT.3



Heparin-Induced Thrombocytopenia (HIT)
Heparin Use
Clinical Consequences of HIT
Thromboembolic Complications (TECs)
Iceberg Model of HIT
Economic Consequences of HIT-Associated TECs
When to Suspect HIT Type 2
Vigilant Monitoring is Critical
General Diagnosis and Treatment Algorithm for HIT
Laboratory confirmation of diagnosis
Terms of Use      Privacy Policy      About Our New Company
Bayer Healthcare Pharmaceuticals